A retrospective analysis of medical records of consecutive breast cancer patients treated in a Chinese hospital from 2018 to 2022 identified 133 patients who met the criteria for VC (approximately 70% Luminal-like, 15% TBNC and 15% HER2+). This evidence concerns the gene ERBB2 and breast carcinoma.